Immunotherapy firm Immatics prices $150 million public offering

11 October 2024

German cancer specialist Immatics (Nasdaq: IMTX) has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners.

This offering follows a series of significant funding rounds in the company’s history. Immatics has previously secured $58 million in a series E financing round and $46 million during its series D.

The firm, which also has a presence in Texas, has developed a partnership Amgen (Nasdaq: AMGN), following a deal worth up to $1 billion, aimed at combining their XPRESIDENT target discovery platform with the latter’s BiTE technology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK